Table 2:
Number of study subjects within each possible scenarios of antibiotic treatment (A1 A2 A3) at the three sequential timepoints corresponding to the empirical, directed, and sustaining treatment periods (T1 T2 T3), together with the proportion of suspected nephrotoxicity that can trigger antibiotic change.
| # | A 1 | A 2 | A 3 | Overall | Suspected Nephrotoxicity | |
|---|---|---|---|---|---|---|
| Yes(N=28) | No(N=39) | |||||
| Time | T 1 | T 2 | T 3 | T1&T2&T3 | T1 − T2 | T1 − T3 |
| 1 | Vancomycin | Vancomycin | Vancomycin | 240(56.2%) | 15(53.6%) | 18(46.2%) |
| 2 | Vancomycin | Vancomycin | Others | 88(20.6%) | 7(25.0%) | 8(20.5%) |
| 3 | Vancomycin | Others | Vancomycin | 38(8.9%) | 1(3.6%) | 6(15.4%) |
| 4 | Vancomycin | Others | Others | 48(11.2%) | 4(14.3%) | 5(12.8%) |
| 5 | Others | Vancomycin | Vancomycin | 3(0.7%) | 0(0%) | 0(0%) |
| 6 | Others | Vancomycin | Others | 2(0.5%) | 0(0%) | 0(0%) |
| 7 | Others | Others | Vancomycin | 2(0.5%) | 0(0%) | 0(0%) |
| 8 | Others | Others | Others | 6(1.4%) | 1(3.6%) | 2(5.1%) |